Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...

Gilead in 2021 won the FDA accelerated nod for Trodelvy in metastatic urothelial cancer, but continued approval was contingent on the outcome of a confirmatory study. The company in late May said that ...

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Current health news covers Gilead's withdrawal of a cancer drug, Texas' lawsuit against a doctor for providing ...

In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.

Antibody-drug Conjugates in Oncology Pipeline Report Introduction 2. Antibody-drug Conjugates in Oncology Pipeline Report Executive Summary ...

The first will accelerate the development of an investigational dispersible... -- This Positive Opinion Could Lead to the Second Indication Based on Overall Survival Data for Trodelvy in Metastatic ...

AstraZeneca/Daiichi Sankyo and Gilead Sciences have reported preliminary ... phase 2 EVOKE-02 study of already-approved TROP2 drug Trodelvy (sacituzumab govitecan), showing what it said was ...